TITLE:

NMMDA informs Healthcare Professionals with regard to safety issues associated with treatment with Thalidomide Celgene (thalidomide)

BRIEF:

According to a direct communication to Healthcare Professionals issued by Celgene Europe Limited and recently published on the website of the National Medicines and Medical Devices Agency (NMMDA), cases of viral activation especially in patients with a history of herpes zoster virus infection or hepatitis b were reported, following treatment with Thalidomide Celgene 50 mg capsule (thalidomide).